title: Clinicopathologic relevance of apoptotic and proliferative factors in human lung adenocarcinoma: Fas expression correlates with the histologic subtype, but not with the degree of apoptosis.
abstract: We immunohistochemically examined 141 surgically resected peripheral lung adenocarcinomas for the expression of Fas, single stranded (ss-) DNA and Ki-67, and statistically evaluated the relationship of these parameters with other clinicopathologic variables, including clinical stage, nodal involvement, and histopathologic subtypes classified according to WHO criteria. Fas expression by cancer cells was characteristically localized in the cytoplasm, and the extent of expression correlated well with the degree of Ki-67 reactivity (p = 0.0004), but not with the degree of apoptic occurrence, as assessed by ss-DNA reactivity. Cancer cells of the bronchioloalveolar carcinoma (BAC) subtype without invasive growth exhibited a significantly lower Fas expression than those of other subtypes (p < 0.0001). Positive expression of Fas was frequently associated with a high incidence of nodal involvement and advanced clinical stage, as compared with cases of negative expression (p = 0.0111 and p = 0.0439, respectively). Multivariate analysis revealed that Fas expression significantly correlated with the histologic subtype, but not with tumor size, nodal involvement, or clinical stage. Survival analysis determined by the log-rank test revealed that clinical stage and Ki-67 reactivity were poor prognostic variables, and Fas expression was not statistically significant. Based on these data, intracytoplasmic expression of Fas in cancer cells may participate in the development of resistance to fas-mediated apoptosis.
authors.affiliation: Division of Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Sepideh
authors.initials: S
authors.lastname: Mojtahedzadeh
authors.forename: Shuichi
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nakashima
authors.forename: Takaomi
authors.initials: T
authors.lastname: Koga
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Matsuo
authors.forename: Ichiro
authors.initials: I
authors.lastname: Yoshino
authors.forename: Kenji
authors.initials: K
authors.lastname: Sugio
authors.forename: Naoko
authors.initials: N
authors.lastname: Kinukawa
authors.forename: Keizo
authors.initials: K
authors.lastname: Sugimachi
authors.forename: Katsuo
authors.initials: K
authors.lastname: Sueishi
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000145:classification / Q000401:mortality / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis; D002455:Cell Division; D004273:DNA, Neoplasm / Q000032:analysis; D004277:DNA, Single-Stranded / Q000032:analysis; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen / Q000032:analysis; D008175:Lung Neoplasms / Q000737:chemistry / Q000145:classification / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D015996:Survival Rate; D019014:fas Receptor / Q000032:analysis*
chemical_list: D004273:DNA, Neoplasm; D004277:DNA, Single-Stranded; D019394:Ki-67 Antigen; D019014:fas Receptor